title: Systemic administration of monosodium glutamate elevates intramuscular glutamate levels and sensitizes rat masseter muscle afferent fibers.
abstract: There is evidence that elevated tissue concentrations of glutamate may contribute to pain and sensitivity in certain musculoskeletal pain conditions. In the present study, the food additive monosodium glutamate (MSG) was injected intravenously into rats to determine whether it could significantly elevate interstitial concentrations of glutamate in the masseter muscle and whether MSG administration could excite and/or sensitize slowly conducting masseter afferent fibers through N-methyl-D-aspartate (NMDA) receptor activation. The interstitial concentration of glutamate after systemic injection of isotonic phosphate-buffered saline (control) or MSG (10 and 50mg/kg) was measured with a glutamate-selective biosensor. The pre-injection baseline interstitial concentration of glutamate in the rat masseter muscle was 24+/-11 microM. Peak interstitial concentration after injection of 50mg/kg MSG was 63+/-18 microM and remained elevated above baseline for approximately 18 min. In vivo single unit recording experiments were undertaken to assess the effect of MSG (50mg/kg) on masseter afferent fibers. Injection of MSG evoked a brief discharge in one afferent fiber, and significantly decreased ( approximately 25%) the average afferent mechanical threshold (n=10) during the first 5 min after injection of MSG. Intravenous injection of ketamine (1mg/kg), 5 min prior to MSG, prevented the MSG-induced decreases in the mechanical threshold of masseter afferent fibers. The present results indicate that a 2- to 3-fold elevation in interstitial glutamate levels in the masseter muscle is sufficient to excite and induce afferent mechanical sensitization through NMDA receptor activation. These findings suggest that modest elevations of interstitial glutamate concentration could alter musculoskeletal pain sensitivity in humans.
authors.affiliation: Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada. brcairns@interchange.ubc.ca
authors.forename: Brian E
authors.initials: BE
authors.lastname: Cairns
authors.forename: Xudong
authors.initials: X
authors.lastname: Dong
authors.forename: Mandeep K
authors.initials: MK
authors.lastname: Mann
authors.forename: Peter
authors.initials: P
authors.lastname: Svensson
authors.forename: Barry J
authors.initials: BJ
authors.lastname: Sessle
authors.forename: Lars
authors.initials: L
authors.lastname: Arendt-Nielsen
authors.forename: Keith M
authors.initials: KM
authors.lastname: McErlane
mesh_terms: D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000344:Afferent Pathways / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D004056:Differential Threshold / Q000187:drug effects*; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism*; D007275:Injections, Intravenous; D008297:Male; D008406:Masseter Muscle / Q000187:drug effects / Q000294:innervation* / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012970:Sodium Glutamate / Q000008:administration & dosage*; D014110:Touch / Q000187:drug effects / Q000502:physiology*
chemical_list: D018698:Glutamic Acid; D012970:Sodium Glutamate